| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
16. A report of the expert panel on cost-effectiveness in health and medicine (sponsored by the US public health service)
|
Kamlet, MarkScott
|
|
1996
|
18 |
S1 |
p. 11-
1 p.
|
artikel
|
| 2 |
C9. A canadian pharmacoeconomic evaluation of zinecard
|
Williamson, T.
|
|
1996
|
18 |
S1 |
p. 24-25
2 p.
|
artikel
|
| 3 |
C3. A cost-density analysis of benign prostatic hyperplasia
|
Lanes, S.
|
|
1996
|
18 |
S1 |
p. 19-20
2 p.
|
artikel
|
| 4 |
C13. Application of medicare databases to a theoretical renal transplant markov model
|
Arnold, R.Goldberg
|
|
1996
|
18 |
S1 |
p. 28-
1 p.
|
artikel
|
| 5 |
C27. A review of pharmacoeconomic studies in Japan
|
Ikeda, S.
|
|
1996
|
18 |
S1 |
p. 39-
1 p.
|
artikel
|
| 6 |
C5. Beyond acute care: the true cost of stroke
|
O'Brien, J.A.
|
|
1996
|
18 |
S1 |
p. 21-
1 p.
|
artikel
|
| 7 |
C11. Clinical and economic effects of Helicobacter pylori screening to prevent gastric cancer
|
Fendrick, A.M.
|
|
1996
|
18 |
S1 |
p. 26-
1 p.
|
artikel
|
| 8 |
C17. Combining multiple quality-of-life domains into aggregate outcome measures: a second-order factor approach
|
Lennox, R.
|
|
1996
|
18 |
S1 |
p. 31-
1 p.
|
artikel
|
| 9 |
C23. Comparative cost outcomes of inhaled corticosteroids for the treatment of asthma
|
Holzer, S.
|
|
1996
|
18 |
S1 |
p. 36-
1 p.
|
artikel
|
| 10 |
C28. Contribution of quasi-experimental research designs in pharmacoeconomic studies: empiric data from a case study of antiviral therapy
|
Itzler, R.F.
|
|
1996
|
18 |
S1 |
p. 40-
1 p.
|
artikel
|
| 11 |
C8. Cost-effectiveness of paclitaxel in advanced ovarian cancer
|
Riviere, M.
|
|
1996
|
18 |
S1 |
p. 24-
1 p.
|
artikel
|
| 12 |
C4. Cost-effectiveness trends of HMG-CoA reductase inhibitor therapy in a managed-care population
|
Petitta, A.
|
|
1996
|
18 |
S1 |
p. 20-21
2 p.
|
artikel
|
| 13 |
C26. Costs of human immunodeficiency virus+/acquired immunodeficiency syndrome at CD4+ counts using treatment protocols
|
Gable, C.
|
|
1996
|
18 |
S1 |
p. 38-39
2 p.
|
artikel
|
| 14 |
C6. Diagnosis of osteoporosis: use of a prescreen questionnaire
|
Lydick, E.
|
|
1996
|
18 |
S1 |
p. 22-
1 p.
|
artikel
|
| 15 |
C10. Economic evaluation of simvastatin in the secondary prevention of coronary heart disease in canada
|
Riviere, M.
|
|
1996
|
18 |
S1 |
p. 25-
1 p.
|
artikel
|
| 16 |
C16. Evaluating quality-of-life and health status instruments: development of scientific review criteria
|
Lohr, K.
|
|
1996
|
18 |
S1 |
p. 30-
1 p.
|
artikel
|
| 17 |
C22. Evaluation of community pharmacy-based anticoagulation clinics
|
Corey, R.
|
|
1996
|
18 |
S1 |
p. 35-
1 p.
|
artikel
|
| 18 |
C2. Guidelines for the use of claims databases for outcomes research
|
Motheral, B.R.
|
|
1996
|
18 |
S1 |
p. 19-
1 p.
|
artikel
|
| 19 |
C7. Hip fractures in the United States: direct medical expenditures within subgroups
|
Martin, A.
|
|
1996
|
18 |
S1 |
p. 23-
1 p.
|
artikel
|
| 20 |
C25. International comparison of the cost of red cell transfusion: Canada and France
|
Souetre, E.
|
|
1996
|
18 |
S1 |
p. 38-
1 p.
|
artikel
|
| 21 |
C14. International economic evaluation of riluzole
|
Leclerc, C.
|
|
1996
|
18 |
S1 |
p. 29-
1 p.
|
artikel
|
| 22 |
C29. Latent variable models of health care utilization and costs for use in pharmacoeconomic research
|
Lennox, R.
|
|
1996
|
18 |
S1 |
p. 41-
1 p.
|
artikel
|
| 23 |
C12. Management and patients with past documented duodenal ulcer but unknown Helicobacter pylori status
|
Fendrick, A.M.
|
|
1996
|
18 |
S1 |
p. 27-
1 p.
|
artikel
|
| 24 |
C30. Methodologic issues in pharmacoeconomic evaluations of HMG-CoA reductase inhibitors used in the treatment of hyperlipidemia
|
Kong, S.X.
|
|
1996
|
18 |
S1 |
p. 41-42
2 p.
|
artikel
|
| 25 |
C19. Quality-adjusted life-years and healthy years equivalent: an empiric comparison
|
Wood, L.L.
|
|
1996
|
18 |
S1 |
p. 32-
1 p.
|
artikel
|
| 26 |
C18. Testing the constant proportional trade-off assumption using standard gamble
|
Bala, M.
|
|
1996
|
18 |
S1 |
p. 31-32
2 p.
|
artikel
|
| 27 |
C15. The economic impact of tacrine in the treatment of Alzheimer's disease
|
Henke, C.
|
|
1996
|
18 |
S1 |
p. 29-30
2 p.
|
artikel
|
| 28 |
C21. The impact of fears on quality of life in a silent disease (osteoporosis)
|
Lydick, E.
|
|
1996
|
18 |
S1 |
p. 34-
1 p.
|
artikel
|
| 29 |
C1. The use of technology assessment and disease management by managed-care pharmacy in the United States
|
Luce, B.R.
|
|
1996
|
18 |
S1 |
p. 18-
1 p.
|
artikel
|
| 30 |
C24. The utilization of a new nonsteroidal anti-inflammatory drug in a health maintenance organization
|
Rader, J.
|
|
1996
|
18 |
S1 |
p. 37-
1 p.
|
artikel
|
| 31 |
C20. Willingness to pay to avoid minor postanesthetic symptoms
|
Orkin, F.
|
|
1996
|
18 |
S1 |
p. 33-
1 p.
|
artikel
|
| 32 |
I13. Advances in statistical considerations in prospective pharmacoeconomic studies
|
Bigelow, RobertH.
|
|
1996
|
18 |
S1 |
p. 17-
1 p.
|
artikel
|
| 33 |
I11. Applications of large databases to evaluate cost-effective therapy
|
Goldberg Arnold, RenéeJ.
|
|
1996
|
18 |
S1 |
p. 15-16
2 p.
|
artikel
|
| 34 |
I5. Draft association for pharmacoeconomics and outcomes research consensus guidance for economic evaluation of pharmaceutical therapy: the health care provider's perspective
|
Finder, Steven
|
|
1996
|
18 |
S1 |
p. 10-
1 p.
|
artikel
|
| 35 |
I2. Guidelines for economic evaluation of pharmaceuticals: Australia—an evolutionary process
|
Mitchell, AndrewS.
|
|
1996
|
18 |
S1 |
p. 7-8
2 p.
|
artikel
|
| 36 |
I1. Guidelines for economic evaluation of pharmaceuticals: Canada's practical experiences
|
Otten, Nicolaas
|
|
1996
|
18 |
S1 |
p. 6-7
2 p.
|
artikel
|
| 37 |
I10. Integration of inpatient and outpatient services: utilizing pharmacoeconomic and outcomes research to guide the way
|
Just, PaulM.
|
|
1996
|
18 |
S1 |
p. 14-
1 p.
|
artikel
|
| 38 |
I3. Pharmacoeconomic evaluations: a pharmaceutical company's perspective
|
Garrison Jr., LouisP.
|
|
1996
|
18 |
S1 |
p. 8-9
2 p.
|
artikel
|
| 39 |
I4. Regulating pharmacoeconomic information: prospects for public and private review in the United States
|
Neumann, PeterJ.
|
|
1996
|
18 |
S1 |
p. 9-
1 p.
|
artikel
|
| 40 |
I12. Statistical considerations in cost-effectiveness evaluations
|
Heyse, JosephF.
|
|
1996
|
18 |
S1 |
p. 16-
1 p.
|
artikel
|
| 41 |
I9. Using pharmacoeconomic research in hospital formulary decisions
|
Gibson, GeneA.
|
|
1996
|
18 |
S1 |
p. 13-
1 p.
|
artikel
|
| 42 |
17. Just the FACCTS—the consumers' perspective on outcomes accountability
|
McNeill, Dwight
|
|
1996
|
18 |
S1 |
p. 11-
1 p.
|
artikel
|
| 43 |
P23. A comparison of the current status of pharmacoeconomic research in Japan and the United States
|
Watrous, M.L.
|
|
1996
|
18 |
S1 |
p. 58-59
2 p.
|
artikel
|
| 44 |
P19. Affectivity and affects balance as highly sensitive measures of psychological outcome and well-being in trials with medical and psychiatric populations
|
Derogatis, L.R.
|
|
1996
|
18 |
S1 |
p. 56-
1 p.
|
artikel
|
| 45 |
P27. A global renal outcomes study using unique data collection and analysis tools
|
Chahal, A.
|
|
1996
|
18 |
S1 |
p. 61-62
2 p.
|
artikel
|
| 46 |
P8. A payer perspective cost-benefit analysis of felbamate in a managed-care setting
|
Klein, E.G.
|
|
1996
|
18 |
S1 |
p. 48-49
2 p.
|
artikel
|
| 47 |
P17. Comparison of family costs of two childhood illnesses—varicella and otitis media
|
Lydick, E.
|
|
1996
|
18 |
S1 |
p. 54-55
2 p.
|
artikel
|
| 48 |
P2. Compromising optimal ambulatory resource utilization: evidence from health services prescribing associated with pharmaceutical products
|
Duttagupta, S.
|
|
1996
|
18 |
S1 |
p. 44-
1 p.
|
artikel
|
| 49 |
P4. Cost demographics of prescribing patterns
|
Nunlee, M.
|
|
1996
|
18 |
S1 |
p. 45-46
2 p.
|
artikel
|
| 50 |
P24. Cost-prevention analysis: a new term for a familiar analysis
|
Copley-Merriman, C.
|
|
1996
|
18 |
S1 |
p. 59-
1 p.
|
artikel
|
| 51 |
P12. Costs of prescription drugs for diabetes mellitus medicaid patients in Alabama: a population-based study
|
Guo, J.J.
|
|
1996
|
18 |
S1 |
p. 51-
1 p.
|
artikel
|
| 52 |
P10. Economic evaluation of drug utilization review on medicaid pharmacy dispensing behavior: an empiric marginal analysis
|
Guo, J.J.
|
|
1996
|
18 |
S1 |
p. 50-
1 p.
|
artikel
|
| 53 |
P11. Effects of drug utilization review on medicaid prescriber behavior: a latent means modeling analysis
|
Guo, J.J.
|
|
1996
|
18 |
S1 |
p. 50-51
2 p.
|
artikel
|
| 54 |
P18. Evaluating red blood cell transfusions using a large clinical database
|
Ollendorf, D.
|
|
1996
|
18 |
S1 |
p. 55-
1 p.
|
artikel
|
| 55 |
Pharmacoeconomics and outcomes research—visions for the 21st century
|
McGhan, WilliamF.
|
|
1996
|
18 |
S1 |
p. 1-4
4 p.
|
artikel
|
| 56 |
P32. Influence of infection on length of hospital stay, mortality, and postdischarge level of care after surgical procedures
|
Bakst, A.W.
|
|
1996
|
18 |
S1 |
p. 65-
1 p.
|
artikel
|
| 57 |
P1. Information management technologies in outcomes research
|
Khan, Z.M.
|
|
1996
|
18 |
S1 |
p. 43-
1 p.
|
artikel
|
| 58 |
P16. Ketorolac does not preemptively reduce postoperative pain following laparoscopic tubal surgery
|
Lee, V.C.
|
|
1996
|
18 |
S1 |
p. 53-54
2 p.
|
artikel
|
| 59 |
P26. Mobile computing with personal digital assistants in a clinical setting
|
Freedman, N.
|
|
1996
|
18 |
S1 |
p. 60-61
2 p.
|
artikel
|
| 60 |
P20. Patient electronic medical record—applications for a new age of treatment data
|
Copeland, K.
|
|
1996
|
18 |
S1 |
p. 56-57
2 p.
|
artikel
|
| 61 |
P9. Patient outcomes: documentation of cost savings and cost avoidance
|
Mutnick, A.
|
|
1996
|
18 |
S1 |
p. 49-
1 p.
|
artikel
|
| 62 |
P21. Pharmacoeconomic analysis in the formulary decision-making process
|
Duong, P.
|
|
1996
|
18 |
S1 |
p. 57-
1 p.
|
artikel
|
| 63 |
P31. Pharmacoeconomic evaluation of oral therapies for onychomycosis: a US model
|
Marchetti, A.
|
|
1996
|
18 |
S1 |
p. 64-65
2 p.
|
artikel
|
| 64 |
P13. Power calculations for peptic disease utilization and expenditure studies
|
Cleary, M.
|
|
1996
|
18 |
S1 |
p. 52-
1 p.
|
artikel
|
| 65 |
P6. Practical issues in conducting pharmacoeconomic studies
|
Rajagopalan, R.
|
|
1996
|
18 |
S1 |
p. 47-
1 p.
|
artikel
|
| 66 |
P5. Present situation of pharmacoeconomic evaluation by Japanese pharmaceutical companies
|
Inoue, S.
|
|
1996
|
18 |
S1 |
p. 46-
1 p.
|
artikel
|
| 67 |
P14. Prevalence rates of antidepressant treatment by sex, age, and health plan
|
Garrard, J.
|
|
1996
|
18 |
S1 |
p. 52-
1 p.
|
artikel
|
| 68 |
P25. PRISM: delivering the pharmacoeconomic message
|
Caro, J.J.
|
|
1996
|
18 |
S1 |
p. 60-
1 p.
|
artikel
|
| 69 |
P22. Quinolone selection in a for-profit hospital: a model for pharmacoeconomics
|
Williams, T.L.
|
|
1996
|
18 |
S1 |
p. 58-
1 p.
|
artikel
|
| 70 |
P15. Rate of esophageal dilations after the introduction of omeprazole
|
Cleary, M.
|
|
1996
|
18 |
S1 |
p. 53-
1 p.
|
artikel
|
| 71 |
18. Providing cost-effective therapy using pharmacoeconomic evaluations: the US public sector approach
|
Finder, Steven
|
|
1996
|
18 |
S1 |
p. 12-
1 p.
|
artikel
|
| 72 |
P33. Staged diabetes management: a complete disease state management
|
Ginsberg, B.H.
|
|
1996
|
18 |
S1 |
p. 66-
1 p.
|
artikel
|
| 73 |
P7. Suboptimal prescribing and related outcomes in the nursing home medicaid elderly
|
Gupta, S.
|
|
1996
|
18 |
S1 |
p. 47-48
2 p.
|
artikel
|
| 74 |
P3. The impact of physician and parent conformance with practice parameters on outcomes of pediatric gastroenteritis
|
Merrick, N.
|
|
1996
|
18 |
S1 |
p. 45-
1 p.
|
artikel
|
| 75 |
P28. The use of markov models in the pharmacoeconomic evaluation of relapsing/remitting diseases
|
Hagan, M.
|
|
1996
|
18 |
S1 |
p. 62-
1 p.
|
artikel
|
| 76 |
P30. The value of pharmacoeconomics in medicare/medicaid programs
|
Goppold, B.
|
|
1996
|
18 |
S1 |
p. 64-
1 p.
|
artikel
|
| 77 |
P29. Use and influence of pharmacoeconomics in decision making in hospitals
|
Gore, M.
|
|
1996
|
18 |
S1 |
p. 63-
1 p.
|
artikel
|
| 78 |
The future of pharmacoeconomics: bridging science and practice
|
Drummond, Michael
|
|
1996
|
18 |
S1 |
p. 5-
1 p.
|
artikel
|
Tijdschrift beschrijving